Expert Perspectives on Immunotherapy for NSCLC: Practical Guidance and Recommendations

Register now for this complimentary educational meeting.

Gain expert perspective on optimal immunotherapy treatment of non-small-cell lung cancer in this 1-hour CME-certified meeting program, which affords the opportunity to interact with the faculty. This program will discuss using immune checkpoint inhibitors, adverse event management, and evaluating emerging therapeutic strategies with this class of agents.


Overview of Immunotherapy for Advanced NSCLC

Clinical Application of Immunotherapy for Advanced NSCLC: Case Discussions

  • Which patients are candidates for checkpoint inhibitors
  • Choice of checkpoint inhibitor

Management of Treatment-Related Adverse Events

Emerging Therapeutic Strategies in Clinical Trials

Question and Answer Session


Date / Time
Event Details


Program Director
Leora Horn, MD, MSc, FRCPC

Associate Professor of Medicine
Clinical Director, Thoracic Oncology
Research Program
Assistant Vice Chairman for Faculty

Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Program Director
Melissa L. Johnson, MD

Associate Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Hossein Borghaei, MS, DO

Associate Professor
Thoracic Medical Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Jamie Chaft, MD

Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Benjamin Creelan, MD

Department of Thoracic Oncology
H. Lee Moffitt Cancer Center and Research
University of South Florida
Tampa, Florida

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Daniel Morgensztern, MD

Assistant Professor
Division of Oncology
Department of Medicine
Washington University
St Louis, Missouri

Rathi Pillai, MD

Assistant Professor
Department of Hematology and Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Karen Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics
City of Hope Comprehensive Cancer Center
Duarte, California

Howard West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington


Goal Statement

The goal of this activity is to improve participants’ competence in integrating immunotherapies into the treatment of patients with non-small-cell lung cancer.

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who provide care for patients with non-small-cell lung cancer.

Learning Objectives

  • Plan treatment strategies using immune checkpoint inhibitors for patients with advanced NSCLC
  • Manage treatment-related adverse events associated with immune checkpoint inhibitors
  • Evaluate the available clinical data on emerging therapeutic strategies using immune checkpoint inhibitors for patients with advanced NSCLC


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.